Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab

Inclusion Criteria

• •During the Screening Epoch:
• •1. Signed informed consent must be obtained prior to participation in the study.
• •2. Adults ≥18 years of age upon entry into screening.
• •3. Patient diagnosed with chronic and high -frequency episodic migraine (with or without aura) for at least 1 year prior to screening according to the International Classification of Headache Disorders-3rd Edition (ICHD-3).
• •4. Patient with a documented diagnosis in clinical history of one or more of the following comorbidities: chronic fatigue, fibromyalgia and/or IBS.
• •5. Patients previously treated with other monoclonal antibodies for migraine can be included if the appropriate washout period according to product half-life has been done for each monoclonal antibody.
• •During the Baseline Epoch:
• •1. Migraine frequency of ≥ 10 migraine days during the Baseline Epoch, confirmed by the eDiary.
• •2. ≥ 80% eDiary compliance during the Baseline Epoch.